Scientists from SRI International and Collaborations Pharmaceuticals in the US have identified a potential new inhibitor, tilorone dihydrochloride, for infection by Ebola virus.
Despite a frantic effort to rush Ebola vaccines through testing during a deadly epidemic, Merck & Co. will fall short of its goal to file its candidate for FDA approval this year, the company confirmed Tuesday.